Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL OLE: Long-Term Extension Study of Infigratinib in Children With Achondroplasia
NCT05145010Phase 2Enrolling by invitation
- Sponsor
- QED Therapeutics
- Start
- Dec 2021
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of infigratinib in achondroplasia (ACH), sponsored by QED Therapeutics. Started Dec 2021; status: enrolling by invitation.
02
Drugs
infigratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05145010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145010.